Biomarkers play an essential role in ovarian cancer treatment and the evolution of personalized medicine. At the same time, understanding how various biomarkers can inform your treatment options can be confusing. In this webinar, Dr. Leslie Boyd, Director of Gynecologic Oncology at Perlmutter Cancer Center, will help make sense of it all by providing an overview of what biomarkers are, noteworthy ones for ovarian cancer, and how they can impact treatment decisions.
Key Takeaways from this Webinar:
Biomarkers are critical to determine eligibility for treatment:
- In frontline treatment (PARPi)
- In recurrent disease
All patients with ovarian cancer should get:
Genetic testing
HRD testing
Molecular testing (in recurrent disease)
Antibody Drug Conjugates (ADCs) are revolutionizing systemic therapy and require a tumor biomarker:
HER 2 and FR alpha are current targets
Many more are on the horizon